Universally available Innate and Adaptive immune cell counts in Acute Ischemic Stroke (AIS) in the context of shared pathobiology with COVID-19; Scoping Review

Tissa Wijeratneabc*, Carmela Salesab, Rohith Menonb, Leila Karimia fh Mihajlo Jakovljeviced,e

a School of Psychology and Public Health, La Trobe University, Melbourne, Australia.

b Department of Neurology, Western Health & University Melbourne, AIMSS, Level three, WHCRE, Sunshine Hospital, St Albans, 3021, Australia.

c Department of Medicine, Faculty of Medicine, University of Rajarata, Saliyapura, Anuradhapura, Sri Lanka.

d Head of Department Global Health Economics & Policy University of Kragujevac Faculty of Medical Sciences, SERBIA

e Professor, Institute of Comparative Economic Studies Hosei University Faculty of Economics, Tokyo, JAPAN

f Faculty of Social and Political Sciences, Tbilisi State University, Georgia

- Corresponding author: tissa.wijeratne@wh.org.au

© 2021 by the author(s). Distributed under a Creative Commons CC BY license.
Abstract: Stroke is one of the leading cause of adult disability and the second leading cause of death worldwide. The immune system actively participates in the pathobiological process of AIS, during the index event and during the repair process despite the limited attention drawn to this aspect in the existing stroke guidelines globally. The similar clinical course and similar circulating innate and adaptive immune cell counts in AIS and COVID-19 has created a renewed interest in these easily available biomarkers innate and adaptive immunological changes in AIS with potential diagnostic, prognostic, and therapeutic implications. The current scoping review aimed to assess the significance of circulating neutrophil and lymphocyte counts and their ratio (NLR) in AIS and explore their association with post-stroke recovery trajectory.

The Arksey and O'Malley methodological framework was employed to review the published papers on the neutrophil-lymphocyte ratio (NLR) and AIS in late November 2020. Only studies published in English from 2000-2020 were included in this scoping review.

Fifty-three published papers were reviewed. This review's key finding is that a canonical inflammatory response occurs in AIS just as in the case of COVID-19 and neurological involvements well described in the recent literature. An excessive circulating innate immune cells (neutrophils) and reduced circulating adaptive immune cells (lymphocytes) are associated with poorer outcomes during the acute interventions (reperfusion therapies) as well as the recovery trajectory. Main representatives of innate and adaptive immunity follow a canonical course in AIS and COVID-19. Exaggerated circulating innate (elevated neutrophils and elevated NLR) and reduced adaptive immune response (lymphopenia) correlate with the worse outcome in AIS and COVID-19. This scoping review's findings make the strongest case for a systems biology-based approach to the standard operating procedures in stroke care urgently.
Keywords: stroke, neutrophil lymphocyte ratio, Systemic Immune Inflammatory Indea, sustainable stroke care

Introduction

On November 12th, 2020, the World Health Assembly (WHA), the global decision-making body of the World Health Organisation (WHO), went on to pass the landmark resolution WHA73.10 for 'global actions on epilepsy and other neurological disorders 'with 13 new paragraphs on key aspects of global brain health as a matter of high priority(1). The resolution confirmed the enormous impact of stroke-related death and disability(2) This was noted to be the main reason behind 80% death(3) and disability(4) in low to middle-income countries worldwide(5, 6). Furthermore, these long term underlying trends among the Emerging BRICS(7) and EM7 Markets play particularly sensitive role shaping the global landscape in epidemiology of stroke and consective challenge of financial sustainability(8).

Stroke is indeed one of the leading causes of disability, and the second leading cause of death worldwide(9). Approximately 85% of strokes are those of Ischaemic origin, and the rest is accounted for by intracerebral and subarachnoid haemorrhage and other types(9). Prognostic assessments are crucial for treatment selection in stroke and remains a challenging aspect for clinicians. Numerous prognostic factors validated by previous studies are not without limitations, including too much emphasis on motor systems, observer-dependent variability and cost(10).

Inflammation plays a key role in AIS from pathobiology, index, and recovery (11-14). Neutrophils and lymphocytes are common markers of inflammation and representatives of innate and adaptive immunity, respectively(15). NLR and systemic immune-inflammatory response (SII) provide an excellent biomarker of the innate and adaptive immune response in AIS just as in the case of COVID-19(16-18). As a cost-effective(19) and easy to perform test in routine
practice, the neutrophil-to-lymphocyte ratio (NLR) has been previously validated as a prognostic indicator in other conditions – cancer, cardiac disease, sepsis, coronary artery disease and metabolic syndrome(20). NLR is obtained from the differential white blood cell count and is calculated by absolute neutrophil count divided by total lymphocyte count.

Methodology

This review included published articles, abstracts, letters and commentaries of neutrophil studies to lymphocyte ratio and its relationship to stroke. In particular, studies were included if they looked into the relation of NLR and ischemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage and post-stroke complications. There were no limitations on the sample size, duration and follow-up. Only studies in English and those that were published from the year 2000 onwards were included.

The following computerized databases were acceded: PUBMED, EMBASE, British Library, Library of Congress and National Lib of Medicine. Each article's bibliography was also manually searched for additional publications. We used the search terms: stroke; Neutrophil to lymphocyte ratio; intracerebral haemorrhage; subarachnoid hemorrhage and post-stroke complications. Two reviewers extracted the data (TW, CS), and a third reviewer (LK) resolved any conflicts for inclusion. The quality of the studies was also independently assessed.

Results

A total of 263 articles were generated from the electronic search. There were 50 duplicates, and the rest were screened on the title level. Further screening of the abstracts yielded 180 articles, of which 47 articles were deemed relevant and included in the study. Additional six studies were included from manual search of bibliographies. Figure 1 shows the PRISMA chart for the search.
Figure 1. PRISMA chart

Identification

Records identified through database searching
N=263

Screening

Duplicates removed
N=213

Abstracts screened
N=180

Records excluded
N=133

Eligibility

Full articles screened for eligibility
N=47

Manual search of bibliographies
N=6

Included

Studies included in the review
N=53
Role of NLR in Acute Ischaemic Stroke

The role of INR has been most widely investigated in ischaemic strokes. Current interventions of acute ischaemic stroke (AIS) include intravenous thrombolysis and mechanical thrombectomy, which aim for recanalization of the cerebral arteries blocked by a clot or an embolus thus resulting in reperfusion of the hypoxic brain tissue. The National Institutes of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) are two prevalent, well-validated scoring systems used to measure stroke severity by quantifying neurological deficits in the former and the degree of dependence of daily activities in the latter.

NLR has been identified to be a useful clinical predictor of outcome in AIS patients being considered for mechanical thrombectomy, as NLR can predict functional dependence and mortality after adjustment for potential confounders that included vascular risk factors. Multiple analyses reveal NLR correlates with a greater functional disability at admission and at three months (increased mRS and NIHSS scores) and increased 90-day mortality (21-27) and was furthermore associated with length of hospital stay(28) and cost(29). Patients with NLR >3.3 were 2-times more likely to be at risk of death(24). This elucidates the role of NLR as a potential biomarker of prognosis, thereby providing an additional level of risk stratification in AIS. Interestingly, high NLR was also significantly correlated with the volume of infarct in anterior circulation strokes but not in those of posterior circulation origin(26). Besides, Switonska identified that elevated NLR was significantly higher in patients treated with both thrombolysis and thrombectomy than those who either received thrombolysis alone or were not
treated. This confirmed that elevated NLR levels were associated with more severe and disabling strokes warranting aggressive treatment(23).

Current literature describes the role of NLR in predicting AIS complications. AIS patients are at risk of developing intracerebral haemorrhage as a complication in the presence or absence of thrombolytic treatment. NLR obtained at 12-18 hours after treatment with intravenous recombinant tissue plasminogen activator (rtPA) was positively associated with haemorrhagic transformation, characterized by symptomatic intracerebral haemorrhage or parenchymal haematomas(30). Many studies identified high NLR values translated to increased haemorrhagic complications (with thrombolysis often intensifying this risk) in AIS(31-33). Other complications with a potential link to high NLR include recurrent ischaemic strokes (34) and infectious sequelae(21, 35). NLR could be used as a predictive marker to monitor and prevent such complications. Promisingly, NLR was also an independent risk factor for the incidence of AIS in generally healthy adults in a study compared with other traditional cardiovascular risk factors, demonstrating the potential of NLR in primary prevention of stroke(36).

The role of INR in AIS and its co-morbid conditions have also been explored. Studies suggest that NLR may reflect the severity of carotid artery stenosis (37-39) and aortic arch calcification(40), both important risk factors of AIS. Nam et al. showed that high NLR could predict early neurological deterioration in cryptogenic stroke patients with active malignancy(41).
Ischaemic injury to the brain triggers a systemic inflammatory response involving brain cells’ activation in the ischaemic area, inducing leucocytes' migration from this area. Neutrophils are described as the first leucocytes to act on the infarcted cells contributing to an enlargement of the area. Lymphocytes accumulate later during the stroke recovery. The high NLR reflects both an amplified innate immune response characterized by higher neutrophils (polymorphonuclear cells) and an attenuated adaptive immune response as demonstrated by decreased lymphocytes(23, 24, 42, 43).

The role of NLR has been explored in neonates and results of a preliminary study demonstrated dynamic changes in NLR following ischaemic brain injury which represent a possible target for therapeutic intervention in this younger subset of patients(44).

NLR and its role in predisposition to Acute Ischemic Stroke

Low-grade systemic inflammation connects metabolic syndrome, cardiovascular diseases such as AIS and aging(45). AIS occurs in the context of a compromised vascular system very much akin to COVID-19 related neurological issues(18, 46-53). The evidence is overwhelming that
activation of innate immunity before and after the AIS and COVID-19 with adaptive immunity implications after the index events of AIS and COVID-19 share similar pathobiology and trajectory. These facts have already been documented so far in large populations of Eur-Asia with prominent public health consequences (54, 55). Unlike its innate counterpart, the adaptive immunity is critically important for the attenuating inflammatory response during the recovery process both in the context of AIS and COVID-19 (See the table one, with kind permission from Wijeratne et al., Frontiers in Neurology, 2021, Under the creative common license (56).
Table 1

| Pathophysiology of COVID-19 and Acute Ischemic Stroke—Chronological Order |
|------------------------------------------------------------------------|
| 1. Binding of SARS-CoV-2 to ACE-2 on the surface of alveolar pneumocytes (ACE2 is the receptor for host cell entry of SARS-CoV-2. ACE-2 is widely expressed on the alveolar epithelial cells, endothelial cells, enterocytes of the small intestine and arterial smooth muscle cells) ([4](#)) |
| 2. Viral infection activates intracellular pattern recognition receptors (PRRs) in the host, PRRs sense pathogen associated molecular patterns (PAMPs) and bind to the receptors on the cell surface, initiating cellular processes such as inflammation, immune responses, and cellular proliferation. ([4](#), [5](#), [6](#), [7](#), [8](#), [9](#)) |
| 3. PAMPs create an inflammatory response that can cause injury to the host cell and tissue. ([4](#), [5](#), [6](#), [7](#), [8](#), [9](#)) |
| 4. Endothelial activation secondary to direct viral activation: The endothelial cells are the first line of defense against viral invasion, and their activation can lead to inflammation and tissue damage. ([4](#), [5](#), [6](#), [7](#), [8](#), [9](#)) |
| 5. Innate immune response with the recruitment of macrophages, neutrophils, and monocytes to the alveoli. ([4](#), [5](#), [6](#), [7](#), [8](#), [9](#)) |
| 6. Further innate immune reaction with T helper cells 1 (Th1) and Th17 T cells and ongoing recruitment of monocytes, macrophages and neutrophils ([5](#), [6](#), [7](#), [8](#), [9](#)) |
| 7. Endothelial activation secondary to direct viral action. ([4](#), [5](#), [6](#), [7](#), [8](#), [9](#)) |
| 8. Endothelial activation secondary to persistent inflammation. ([4](#), [5](#), [6](#), [7](#), [8](#), [9](#)) |
| 9. Recruitment of intravascular neutrophils. ([4](#), [5](#), [6](#), [7](#), [8](#), [9](#)) |

*Attempt has been made to assimilate all available current evidence to formulate this table. However, we are aware that the pandemic is still evolving, and additional molecular mechanisms and pathways are likely to be discovered as time goes by.

While neutrophils play a key role in the innate immune response, lymphocytes with their wide range of cellular phenotypes play a crucial role in regulating the adaptive immune response. The key role of NLR in pathobiology, progress and prognostication of AIS should be the expectation rather than the exception. While NLR has been used as a prognosticating index in patients with various stroke mechanisms, it has also been employed to determine stroke risk in healthy and among patients with other pathologic conditions. Elevated values, especially among normal subjects, highlight the importance of subtle and ongoing chronic inflammation and its predisposition to pathologies such as diabetes and stroke([36](#), [57](#)).
In a retrospective literature published by Suh et al., it has been demonstrated that among almost 25,000 normal subjects, elevated NLR is a risk factor for ischemic stroke\(^{(36)}\). This study further concluded that the addition of NLR improved the Framingham risk for reclassification of ischemic stroke\(^{(36)}\). On the other hand, patients with preexisting cardiovascular risk factors are also prone to stroke if NLR is elevated\(^{(58)}\). A study of more than 32,000 atrial fibrillation subjects without prior anticoagulation were prospectively followed up for the first-ever stroke and has been shown that independent of patients' CHADS-Vasc scores; there is a dose-dependent increase in the incidence of stroke with increasing NLR quartiles which were estimated to be 2.27, 2.72, 3.26 and 4.54 per 100 person-years, respectively\(^{(58)}\). This is further corroborated in another study that compared patients with AF with and without stroke suggesting that patients belonging to the former had a higher NLR than their non-stroke counterparts\(^{(59)}\). Moreover, Min et al. also concluded that aside from AF, NLR was also positively correlated to NIHSS and diabetes among ischemic stroke patients\(^{(59)}\).

It is clear that both AF and stroke are related to a state of chronic inflammation which may be manifested serologically by the dissociation of neutrophils and lymphocytes\(^{(58, 59)}\). The occurrence of stroke among patients with AF is linked to the formation of a cardiac thrombus, which is also linked to a higher NLR state\(^{(56)}\). In animal models, there has been a success in using corticosteroids in minimizing atrial-tissue related inflammation which contributes to a pro-arrhythmic state, but this has yet to be fully evaluated in humans\(^{(60)}\). There is also limited information on anti-inflammatory agents in stroke prevention, particularly in AF patients.
NLR and its role in post-stroke complications

1. Stroke Associated Pneumonia

Stroke Associated Pneumonia (SAP), an occurrence in almost 14.6% of all stroke patients, is one of the most significant acute stroke complications.58 It is an important risk factor for mortality at one and six months, with death rates at 19% and 44%, respectively(61). The Neutrophil to lymphocyte ratio on admission has also been explored as a prognostic indicator for pneumonia among stroke patients. Nam et al. observed that patients with higher NLR presented with more prolonged hospitalization and higher NIHSS(62). Furthermore, a higher frequency of mortality at one month and worse MRS at three months was observed among patients with higher NLR(62). Compared to other parameters such as white blood cell, absolute Neutrophil and lymphocyte count, an elevated NLR on admission was also associated with a higher risk of mortality after 90 days(63).

While impairment in swallowing mechanisms largely contributes to pneumonia among post-stroke patients, there is increasing evidence that stroke itself induces an immunocompromised state predisposing patients to infection(64). This is supported by observations of decreased lymphocyte number and an increase in neutrophil count in acute stroke patients(65). While targeted neutrophil therapy may have the theoretical advantage, Ruhnau recommends that therapy's potential benefits may be countered by its opposing effects in the brain and systemically(65). This is made true in a clinical trial of an anti-inflammatory drug Enlimomab on patients with ischemic stroke (Enlimomab)(66). Comparing the former with placebo, it has
been shown that among Enlimomab-treated patients, there were more serious adverse events, particularly fever and infection, and higher mortality rates(66).

2. Post-stroke delirium

Delirium is another complication known to occur in 13% to 48% of patients with acute stroke(67). There is clinical data to suggest that risk of death, institutionalization and hospital stay is significantly higher among stroke patients with delirium(68). The use of the Neutrophil to lymphocyte ratio as a prognostic factor in patients with delirium was first explored by Egberts et al. in acutely ill patients(69). This study's results, which involves 86 patients, prove that patients who are clinically unwell and subsequently develop delirium have higher NLR(69).

A prospective observational study of 1001 patients with acute ischemic stroke diagnosed with delirium using the CAM-ICU (Confusion Assessment Method for Intensive Care Unit) corroborated this condition's increased incidence as previously observed in other studies(70). In the same study, along with NLR, clinical (hemianopia, aphasia, NIHSS) and laboratory variables (leukocytes and CRP) which comprise the Delirium in Acute Ischemic Stroke (DELIAS) score, this has been shown to have good predictive value for detecting early-onset delirium and of moderate predictive value for delirium up to the fifth day from the stroke(70). On the other hand, a follow-up study of patients with first-ever acute ischemic stroke has shown that instead of NLR, platelet to white cell count ratio was associated with early delirium occurrence (71). These studies support previous evidence that acute brain injury may result in the loss of adaptation of the immune cells as manifested by the disproportionate changes of hematologic parameters(70, 71).
3. Post Stroke Depression

Depression is one of the leading causes of morbidity among stroke patients and significantly impacts all aspects of rehabilitation (72). A meta-analysis including seven studies involving more than 17,000 patients has shown that post-stroke depression (PSD) is associated with increased risk of mortality with a relative risk of 1.50 (95% CI: 1.28 to 1.75; p < 0.001) (73). One of the key implicated mechanisms is neurobiological systems’ involvement, emphasizing post-stroke inflammation, which is the expectation rather than the exception (74-76). Grundy and colleagues have demonstrated that inflammatory mediators produced after acute stroke may have damaging effects on rat models (77). It has been further proposed that the production of IL-1 and other chemokines by mononuclear phagocytes attracts neutrophils, monocytes and T-lymphocytes which further play a role in the dysregulation of humoral and inflammatory systems and maybe indirectly correlated to its pathogenesis (75).

The Neutrophil’s use to lymphocyte ratio as a predictor for depression among stroke patients has been well documented in the literature (78-80). In a prospective study involving 299 ischemic stroke patients, increased NLR during admission was correlated to PSD after one month, with diagnosis based on the 17-Hamilton rating scale (81). Using the Quick Inventory for Depression Symptomology (QIDS), Wolde et al. showed the positive correlation between high NLR on acute stroke presentation and the occurrence of depression after 30 days (79). A retrospective study of more than 300 patients also demonstrated that in conjunction with platelet to lymphocyte ratio, high admission NLR is associated with depression at six months after
stroke(82). On the other hand, a correlation of depression severity has also been demonstrated with increasing NLR among patients without stroke but with significant vascular risk factors(83).

**Future Potential Therapeutic Opportunities**

The unmet needs in stroke prevention and post stroke rehabilitation continue to remain an immense challenge to the world. It is clear that the human immune system is quite complex with synergistic (innate immune cells and mechanisms) as well as antagonistic (adaptive immune cells and mechanisms) roles with different cells playing different roles at different time points of AIS with likely shared pathobiology with COVID-19, other vascular diseases such as ischemic heart disease, acute myocardial infarction in particular(84-87). Innate and adaptive immune cells and pathways should complement each other's for an effective and optimum recovery process after the index event of AIS. This aspect has not been considered or explored by any existing national or international stroke guidelines and standard operating procedures at present (Wijeratne et al., Manuscript in submission). Patients with an already compromised vascular system with AIS appear to show elevated NLR, suggesting an undue prominence of circulating neutrophils (innate immune cells) over lymphocytes (adaptive immune cells). This means the potential therapeutic targets such as reducing the innate immune system's hyperactivity while minimizing the depression of the adaptive immune system during the index event of AIS. There may be a role for safe, low cost, psycho-neuro-immuno-modulatory chemicals such as melatonin and curcumin with potential therapeutic benefits in disabling post-stroke complications post-stroke depression, post-stroke fatigue, post-stroke anxiety etc(88).
To date, the use of anti-inflammatory agents in post-stroke depression is minimally explored. Studies have shown that SSRI, one of the mainstays for PSD treatment, exhibits an anti-inflammatory activity by upregulating neurotrophins and enhancing neurogenesis (89-91). A meta-analysis involving 14 publications with more than 6,000 patients, has shown that nonsteroidal inflammatory drugs, most notably Celecoxib, alleviate depressive symptoms compared to placebo (92). There is also evidence that Celecoxib and Infliximab's intake in patients with major depression has resulted in a concomitant decrease of the inflammatory markers, IL-6 and CRP, respectively (93, 94). While anti-inflammatory agents' role in depression seems to be promising, further studies are needed, especially among post-stroke patients, given the former's association with vascular events (95).

Conclusion

The Neutrophil to lymphocyte ratio is a cheap, effective, yet an underutilized biological marker in AIS. It provides information on prognosis and risk stratification among stroke patients and individuals who are at risk of developing neurovascular events. The NLR and immune-based simple algorithms such as systemic immune-inflammatory index (SII), Sunshine Prognostic Score (SPS) provide substantial, systems based comprehensive biological information on a stroke patient's degree of chronic inflammation be associated with different clinical outcomes and different therapeutic potentials (56, 96-98). While animal studies have proven the theoretical role of anti-inflammatory drugs in controlling the damaging the degree of systemic and neuro-inflammation, this has not translated significantly in human clinical trials.
The recently concluded 73rd WHA confirmed the enormity of challenges ahead to the world. The 73rd WHA makes the strongest argument for synergy between researchers, academics, government and non-governmental sectors, hospitals to tackle the growing number of neurological disorders as a matter of high priority. Stroke remains the largest contributor to global death and disability. Systems biology-based approach in AIS management should provide the best synergy to bring the best care for AIS throughout the recovery trajectory.
References

1. Wijeratne T. Interview with WFN president on World Health Assembly endorsement of resolutions on epilepsy and neurological disorders World Federation of Neurology 2020 [Available from: https://wfneurology.org/news/wfn-news/2020-11-15-wfn.
2. Jakovljevic M, Sugahara T, Timofeyev Y, Rancic N. Predictors of (in)efficiencies of Healthcare Expenditure Among the Leading Asian Economies - Comparison of OECD and Non-OECD Nations. Risk Manag Healthc Policy. 2020;13:2261-80.
3. Feigin VL, Abajobir AA, Abate KH, Abd-Allah F, Abdulle AM, Abersa SF, et al. Global, regional, and national burden of neurological disorders during 1990 & 2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology. 2017;16(11):877-97.
4. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990 & 2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2019;18(5):459-80.
5. Feigin VL, Norrow B, Mensah GA. Global Burden of Stroke. Circ Res. 2017;120(3):439-48.
6. Jakovljevic M, Potapchik E, Popovich L, Barik D, Getzen TE. Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025. Health Economics. 2017;26(7):844-52.
7. Jakovljevic M. The Key Role of the Leading Emerging Bric Markets in the Future of Global Health Care. Serbian Journal of Experimental and Clinical Research. 2014;15:139 - 43.
8. Jakovljevic M, Timofeyev Y, Ranabhat CL, Fernandes PO, Teixeira JP, Rancic N, et al. Real GDP growth rates and healthcare spending – comparison between the G7 and the EM7 countries. Globalization and Health. 2020;16(1):64.
9. Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, Parimar PG, et al. The GBD 2016 Lifetime Risk of Stroke Collaborators. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. New England Journal of Medicine. 2018;379(25):2429-37.
10. Gao MM, Wang J, Saposnik G. The Art and Science of Stroke Outcome Prognostication. Stroke. 2020;51(5):1358-60.
11. Amruta N, Rahman AA, Pinteaux E, Bix G. Neuroinflammation and fibrosis in stroke: The good, the bad and the ugly. J Neuroimmunol. 2020;346:577318.
12. Anrather J, Iadecola C. Inflammation and Stroke: An Overview. Neurotherapeutics. 2016;13(4):661-70.
13. Chamorro A. Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis. 2004;17 Suppl 3:1-5.
14. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17(7):796-808.
15. Nguyen VA, Crewther SG, Howells DW, Wijeratne T, Ma H, Hankey GJ, et al. Acute Routine Leukocyte and Neutrophil Counts Are Predictive of Poststroke Recovery at 3 and 12 Months Poststroke: An Exploratory Study. Neurorehabil Neural Repair. 2020;34(9):844-55.
16. Song S-Y, Zhao X-X, Rajah G, Hua C, Kang R-J, Han Y-P, et al. Clinical Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Patients With Ischemic Stroke or Hemorrhagic Stroke: An Updated Meta-Analysis. Frontiers in neurology. 2019;10:1032-.
17. Wijeratne T, Menon R, Sales C, Karimi L, Crewther S. Carotid artery stenosis and inflammatory biomarkers: the role of inflammation-induced immunological responses affecting the vascular systems. Annals of Translational Medicine. 2020;8(19).
18. Wijeratne T, Sales C, Karimi L, Crewther SG. Acute Ischemic Stroke in COVID-19: A Case-Based Systematic Review. Frontiers in Neurology. 2020;11(1031).
19. Jakovljevic M, Matter-Walstra K, Sugahara T, Sharma T, Reshetnikov V, Merrick J, et al. Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow. Cost Eff Resour Alloc. 2020;18:15-.
20. Liu CC, Ko HJ, Liu WS, Hung CL, Hu KC, Yu LY, et al. Neutrophil-to-lymphocyte ratio as a predictive marker of metabolic syndrome. Medicine (Baltimore). 2019;98(43):e17537.
21. Wang L, Song Q, Wang C, Wu S, Deng L, Li Y, et al. Neutrophil to lymphocyte ratio predicts poor outcomes after acute ischemic stroke: A cohort study and systematic review. J Neurol Sci. 2019;406:116445.
22. Fan L, Gui L, Chai EQ, Wei CJ. Routine hematological parameters are associated with short- and long-term prognosis of patients with ischemic stroke. J Clin Lab Anal. 2018;32(2).
23. Świtonska M, Piekuś-Stomka N, Słomka A, Sokal P, Żekanowska E, Lattanzi S. Neutrophil-to-Lymphocyte Ratio and Symptomatic Hemorrhagic Transformation in Ischemic Stroke Patients Undergoing Revascularization. Brain Sci. 2020;10(11).
24. Brooks SD, Spears C, Cummings C, VanGilder RL, Stinehart KR, Gutmann L, et al. Admission neutrophil-lymphocyte ratio predicts 90 day outcome after endovascular stroke therapy. J Neurointerv Surg. 2014;6(8):578-83.
25. Giede-Jeppe A, Madžar D, Sembill JA, Sprügel MI, Atay S, Hoelter P, et al. Increased Neutrophil-to-Lymphocyte Ratio is Associated with Unfavorable Functional Outcome in Acute Ischemic Stroke. Neurocrit Care. 2020;33(1):97-104.
26. Kocaturk O, Besli F, Gungoren F, Kocaturk M, Tanriverdi Z. The relationship among neutrophil to lymphocyte ratio, stroke territory, and 3-month mortality in patients with acute ischemic stroke. Neuror Sci. 2019;40(1):139-46.
27. Lim HH, Jeong IH, An GD, Woo KS, Kim KH, Kim JM, et al. Early prediction of severity in acute ischemic stroke and transient ischemic attack using platelet parameters and neutrophil-to-lymphocyte ratio. J Clin Lab Anal. 2019;33(3):e22714.
28. Jakovljevic M, Jakab M, Gerdstham U, McDaid D, Ogura S, Varavikova E, et al. Comparative financing analysis and political economy of noncommunicable diseases. Journal of Medical Economics. 2019;22(8):722-7.
29. Zhao L, Dai Q, Chen X, Li S, Shi R, Yu S, et al. Neutrophil-to-Lymphocyte Ratio Predicts Length of Stay and Acute Hospital Cost in Patients with Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2016;25(4):739-44.
30. Guo Z, Yu S, Xiao L, Chen X, Ye R, Zheng P, et al. Dynamic change of neutrophil to lymphocyte ratio and hemorrhagic transformation after thrombolysis in stroke. J Neuroinflammation. 2016;13(1):199.
31. Maestrini I, Strbian D, Gautier S, Haapaniemi E, Moulin S, Sairanen T, et al. Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology. 2015;85(16):1408-16.
32. Pikija S, Sztriha LK, Killer-Oberpfalzer M, Weymayr F, Hecker C, Ramesmayer C, et al. Neutrophil to lymphocyte ratio predicts intracranial hemorrhage after endovascular thrombectomy in acute ischemic stroke. J Neuroinflammation. 2018;15(1):319.
33. Zhang R, Wu X, Hu W, Zhao L, Zhao S, Zhang J, et al. Neutrophil-to-lymphocyte ratio predicts hemorrhagic transformation in ischemic stroke: A meta-analysis. Brain Behav. 2019;9(9):e01382.
34. Xue J, Huang W, Chen X, Li Q, Cai Z, Yu T, et al. Neutrophil-to-Lymphocyte Ratio Is a Prognostic Marker in Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases. 2017;26(3):650-7.
35. Giede-Jeppe A, Bobinger T, Gerner ST, Sembill JA, Sprügel MI, Beuscher VD, et al. Neutrophil-to-Lymphocyte Ratio Is an Independent Predictor for In-Hospital Mortality in Spontaneous Intracerebral Hemorrhage. Cerebrovasc Dis. 2017;44(1-2):26-34.

36. Suh B, Shin DW, Kwon HM, Yun JM, Yang HK, Ahn E, et al. Elevated neutrophil to lymphocyte ratio and ischemic stroke risk in generally healthy adults. PLoS One. 2017;12(8):e0183706.

37. Wijeratne T, Menon R, Sales C, Karimi L, Crewther S. Carotid artery stenosis and inflammatory biomarkers: the role of inflammation-induced immunological responses affecting the vascular systems. Annals of Translational Medicine. 2020.

38. Hyun S, Kwon S, Cho S, Park S, Jung W, Moon S, et al. Can the Neutrophil-to-Lymphocyte Ratio Appropriately Predict Carotid Artery Stenosis in Patients with Ischemic Stroke? - A Retrospective Study. J Stroke Cerebrovasc Dis. 2015;24(11):2646-51.

39. Jiang H, Zhang J, Wu J, Wei G, He Y, Gao X. Neutrophil-to-Lymphocyte Ratio Correlates with Severity of Extracranial Carotid Stenosis - A Study Using Digital Subtraction Angiography. J Stroke Cerebrovasc Dis. 2017;26(6):1182-90.

40. Zhou S, Cai B, Zhang Y, Wang L, Liu X, Xu G. The Relationship between Neutrophil-to-Lymphocyte Ratio and Aortic Arch Calcification in Ischemic Stroke Patients. J Stroke Cerebrovasc Dis. 2017;26(6):1228-32.

41. Nam KW, Kim TJ, Kim CK, Mo H, Jeong HY, Kang MK, et al. Temporal changes in the neutrophil to lymphocyte ratio and the neurological progression in cryptogenic stroke with active cancer. PLoS One. 2018;13(3):e0194286.

42. Semerano A, Laredo C, Zhao Y, Rudilosso S, Renú A, Llull L, et al. Leukocytes, Collateral Circulation, and Reperfusion in Ischemic Stroke Patients Treated With Mechanical Thrombectomy. Stroke. 2019;50(12):3456-64.

43. Semerano A, Strambo D, Martino G, Comi G, Filippi M, Roveri L, et al. Leukocyte Counts and Ratios Are Predictive of Stroke Outcome and Hemorrhagic Complications Independently of Infections. Front Neurol. 2020;11:201.

44. Povroznik JM, Englert-Chiurazzi EB, Nanavati T, Pergami P. Absolute lymphocyte and neutrophil counts in neonatal ischemic brain injury. SAGE Open Med. 2018;6:2050312117752613.

45. Guarner V, Rubio-Ruiz ME. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Interdiscip Top Gerontol. 2015;40:99-106.

46. Tissa Wijeratne CS, Leila Karimi and Sheila Gillard Crewther. Acute Ischemic Stroke in COVID-19: A case-based systematic review. Frontiers in Neurology. 2020.

47. Tissa Wijeratne SGC, Tissa Wijeratne. What is Post Covid19 Neurological Syndrome? University of Melbourne: University of Melbourne; 2020 [Available from: https://pursuit.unimelb.edu.au/articles/what-is-post-covid-19-neurological-syndrome?fbclid=IwAR1H5RVh7Fmr9orgYst2c-N5dhjFz1Ybxmlu-hEhTP4M5AUSo_hbXVjo-1w.

48. Wijeratne T, Crewther S. Post-COVID 19 Neurological Syndrome (PCNS): a novel syndrome with challenges for the global neurology community. J Neurol Sci. 2020;419:117179.

49. Wijeratne T, Crewther S. Post-COVID 19 Neurological Syndrome (PCNS): a novel syndrome with challenges for the global neurology community. J Neurol Sci. 2020;419:117179-.

50. Wijeratne T, Crewther S, Sales C, Karimi L. COVID-19 pathophysiology predicts that neurological manifestations are an expectation, not an exception Frontiers in Neurology. 2020.

51. Wijeratne T, Sales C, Karimi L, Crewther SG. Acute Ischemic Stroke in COVID-19: A Case-Based Systematic Review. Front Neurol. 2020;11:1031.

52. Wijeratne T, Sales C, Karimi L, Crewther SG. Acute ischemic stroke in COVID-19: a case-based systematic review. Frontiers in Neurology. 2020;11.
53. Wijeratne T, Sales CA, Crewther SG, Nguyen V, Karimi L. First Australian Case of Good Recovery of a COVID-19 Patient With Severe Neurological Symptoms Post Prolonged Hospitalization. Cureus. 2020;12(9):e10366.
54. Grima S, Kizilkaya M, Rupeika-Apoga R, Romānova I, Dalli Gonzi R, Jakovljevic M. A Country Pandemic Risk Exposure Measurement Model. Risk Manag Healthc Policy. 2020;13:2067-77.
55. Reshetnikov V, Mitrokhin O, Shepetovskaya N, Belova E, Jakovljevic M. Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience. Expert Review of Pharmacoeconomics & Outcomes Research. 2020;20(6):571-6.
56. Wijeratne T, Crewther S, Karimi L. COVID-19 pathophysiology predicts that ischemic stroke occurrence is an expectation, not an exception—a systematic review. Frontiers in Neurology. 2021.
57. Duman TT, Aktas G, Atak BM, Kocak MZ, Erkus E, Savli H. Neutrophil to lymphocyte ratio as an indicative of diabetic control level in type 2 diabetes mellitus. Afr Health Sci. 2019;19(1):1602-6.
58. Saliba W, Barnett-Griness O, Elias M, Rennert G. Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: a cohort study. Journal of Thrombosis and Haemostasis. 2015;13(11):1971-9.
59. Min K, Kwon S, Cho SY, Choi WJ, Park SU, Jung WS, et al. Atrial Fibrillation is Strongly Associated With the Neutrophil to Lymphocyte Ratio in Acute Ischemic Stroke Patients: A Retrospective Study. J Clin Lab Anal. 2017;31(2).
60. Calvo D, Filgueiras-Rama D, Jalife J. Mechanisms and Drug Development in Atrial Fibrillation. Pharmacol Rev. 2018;70(3):505-25.
61. Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, Di Napoli M, et al. How is pneumonia diagnosed in clinical stroke research? A systematic review and meta-analysis. Stroke. 2015;46(5):1202-9.
62. Nam KW, Kim TJ, Lee JS, Kwon HM, Lee YS, Ko SB, et al. High Neutrophil-to-Lymphocyte Ratio Predicts Stroke-Associated Pneumonia. Stroke. 2018;49(8):1886-92.
63. Wang L, Guo W, Wang C, Yang X, Hao Z, Wu S, et al. Dynamic Change of Neutrophil to Lymphocyte Ratios and Infection in Patients with Acute Ischemic Stroke. Curr Neurovasc Res. 2020;17(3):294-303.
64. Feng HX, Cheng Y, Zhu W, Jiang LL, Dong XF, Gui Q, et al. T-lymphocyte subsets as a predictive biomarker for stroke-associated pneumonia. Am J Transl Res. 2018;10(12):4367-75.
65. Ruhnau J, Schulze J, Dressel A, Vogelgesang A. Thrombosis, Neuroinflammation, and Poststroke Infection: The Multifaceted Role of Neutrophils in Stroke. J Immunol Res. 2017;2017:5140679.
66. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology. 2001;57(8):1428-34.
67. Oldenbeuving AW, de Kort PLM, Jansen BPW, Roks G, Kappelle LJ. Delirium in Acute Stroke: A Review. International Journal of Stroke. 2007;2(4):270-5.
68. Shi Q, Presutti R, Selchen D, Saposnik G. Delirium in acute stroke: a systematic review and meta-analysis. Stroke. 2012;43(3):645-9.
69. Egberts A, Mattace-Raso FU. Increased neutrophil-lymphocyte ratio in delirium: a pilot study. Clin Interv Aging. 2017;12:1115-21.
70. Kotfis K, Bott-Olejnik M, Szylinska A, Rotter I. Could Neutrophil-to-Lymphocyte Ratio (NLR) Serve as a Potential Marker for Delirium Prediction in Patients with Acute Ischemic Stroke? A Prospective Observational Study. J Clin Med. 2019;8(7).
71. Kotfis K, Bott-Olejnik M, Szylinska A, Listewnik M, Rotter I. Characteristics, Risk Factors And Outcome Of Early-Onset Delirium In Elderly Patients With First Ever Acute Ischemic Stroke - A Prospective Observational Cohort Study. Clinical interventions in aging. 2019;14:1771-82.
72. Das J, G KR. Post stroke depression: The sequelae of cerebral stroke. Neurosci Biobehav Rev. 2018;90:104-14.
73. Bartoli F, Di Brita C, Crocamo C, Clerici M, Carrà G. Early Post-stroke Depression and Mortality: Meta-Analysis and Meta-Regression. Frontiers in psychiatry. 2018;9:530-.
74. Ferrari F, Villa RF. The Neurobiology of Depression: an Integrated Overview from Biological Theories to Clinical Evidence. Mol Neurobiol. 2017;54(7):4847-65.
75. Spalletta G, Bossù P, Ciaramella A, Bria P, Caltagirone C, Robinson RG. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Molecular Psychiatry. 2006;11(11):984-91.
76. Pascoe MC, Crewther SG, Carey LM, Crewther DP. Inflammation and depression: why poststroke depression may be the norm and not the exception. Int J Stroke. 2011;6(2):128-35.
77. Grundy RI, Rothwell NJ, Allan SM. Site-specific actions of interleukin-1 on excitotoxic cell death in the rat striatum. Brain Research. 2002;926(1):142-8.
78. Chen H, Luan X, Zhao K, Qiu H, Liu Y, Tu X, et al. The association between neutrophil-to-lymphocyte ratio and post-stroke depression. Clinica chimica acta; international journal of clinical chemistry. 2018;486:298-302.
79. Lucke-Wold AN, Regier MD, Petrone A, Tennant C, Barr T. Abstract TMP80: Relationship Between Neutrophil/Lymphocyte Ratio and Post-stroke Depression. Stroke. 2016;47(suppl_1):ATMP80-ATMP.
80. Hu J, Zhou W, Zhou Z, Han J, Dong W. Elevated neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict post-stroke depression with acute ischemic stroke. Exp Ther Med. 2020;19(4):2497-504.
81. Aydin Sunbul E, Sunbul M, Yanartas O, Cengiz F, Bozbay M, Sari I, et al. Increased Neutrophil/Lymphocyte Ratio in Patients with Depression is Correlated with the Severity of Depression and Cardiovascular Risk Factors. Psychiatry Investig. 2016;13(1):121-6.
82. Chamorro A, Planas AM. Inflammation-mediated damage as a potential therapeutic target in acute ischemic stroke. Ernst Schering Res Found Workshop. 2004(47):185-204.
83. Planas AM. Role of Immune Cells Migrating to the Ischemic Brain. Stroke. 2018;49(9):2261-7.
84. de Dios E, Rios-Navarro C, Perez-Sole N, Gavara J, Marcos-Garcés V, Rodríguez E, et al. Similar Clinical Course and Significance of Circulating Innate and Adaptive Immune Cell Counts in STEMI and COVID-19. Journal of clinical medicine. 2020;9(11):3484.
85. Wijeratne T CS, Sales C,Karimi L. COVID-19 pathophysiology predicts that neurological manifestations are an expectation, not an exception Frontiers in Neurology. 2020.
86. Jakovljevic M, Lazarevic M, Milovanovic O, Kanjevac T. The New and Old Europe: East-West Split in Pharmaceutical Spending. Frontiers in Pharmacology. 2016;7(18).
87. Villa A, Vegefo E, Poloett A, Maggi A. Estrogens, Neuroinflammation, and Neurodegeneration. Endocr Rev. 2016;37(4):372-402.
88. Villa RF, Ferrari F, Moretti A. Post-stroke depression: Mechanisms and pharmacological treatment. Pharmacol Ther. 2018;184:131-44.
89. Villanueva C, Kross RD, Pérez-Astudillo L. Free radicals and neuronal recovery from an ischaemic penumbra: A review. Free Radicals and Diseases: IntechOpen; 2016.
90. Köhler O, Benros ME, Nordentoft M, Farkhou ME, Iyengar RL, Mors O, et al. Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Psychiatry. 2014;71(12):1381-91.
93. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141(2-3):308-14.

94. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41.

95. Chen YR, Hsieh FI, Chang CC, Chi NF, Wu HC, Chiou HY. Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis. Am J Cardiol. 2018;121(10):1271-7.

96. Wijeratne T, Crewther S. COVID-19 and long-term neurological problems: Challenges ahead with Post-COVID-19 Neurological Syndrome. Aust J Gen Pract. 2021;50.

97. Wijeratne T, Gillard Crewther S, Sales C, Karimi L. COVID-19 Pathophysiology Predicts That Ischemic Stroke Occurrence Is an Expectation, Not an Exception—A Systematic Review. Frontiers in Neurology. 2021;11(1759).

98. Wijeratne T, Wijeratne C, Karimi L, Sales C, Crewther SG. Case Report: Posterior Reversible Leukoencephalopathy Syndrome (PRES) as a Biologically Predictable Neurological Association in Severe COVID-19. First Reported Case From Australia and Review of Internationally Published Cases. Frontiers in Neurology. 2021;11(1759).